The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendationSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE ...

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...

Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The clinical-stage ...

Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to ...

While architectural, museum-worthy nail art is a delight to behold and just as fun to wear, some folks are in the camp of ...

Getting rid of the military’s top lawyers is not exactly a sign that the Trump administration wants to follow the law.

SBK: Hiroyuki Seki: "we have been out of World Superbike 10 years and we are still learning. The tyres have evolved and we ...

As Meghan’s new Netflix show airs for the first time, Tanya Gold explores the complex, heartbreaking and deeply unhealthy ...

Callista’s hobo bag has all the storage you’d ever need. Perfect for pocket-lovers, this bag ensures all your daily ...